Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Paolo Olgiati"'
Autor:
Paolo Olgiati, Antonis M. Politis, George N. Papadimitriou, Diana De Ronchi, Alessandro Serretti
Publikováno v:
International Journal of Alzheimer's Disease, Vol 2011 (2011)
The genetics of late-onset Alzheimer's disease (LOAD) has taken impressive steps forwards in the last few years. To date, more than six-hundred genes have been linked to the disorder. However, only a minority of them are supported by a sufficient lev
Externí odkaz:
https://doaj.org/article/17994fadd66b4548ab2403ee47cb1ee6
Autor:
Alessandro Serretti, Paolo Olgiati
Publikováno v:
Zdravniški Vestnik, Vol 76, Iss 0 (2007)
Izhodišča: Pri zdravljenju z antidepresivi velik problem predstavlja neodzivnost na zdravljenje, ki je ni mogoče vnaprej napovedati, pojavi pa se kar pri tretjini bolnikov. S farmakogenetskim pristopom so v zadnjih letih odkrili številne genetske
Externí odkaz:
https://doaj.org/article/90a0bc77bd74437ab605fb0e4fe118e4
Autor:
Paolo Olgiati, Alessandro Serretti
Publikováno v:
International Clinical Psychopharmacology. 38:184-186
Publikováno v:
International Clinical Psychopharmacology, 37, 6, pp. 247-254
International Clinical Psychopharmacology, 37, 247-254
International Clinical Psychopharmacology, 37, 247-254
Binge-eating (BE) symptoms are relatively common in major depressive disorder (MDD), but their prognostic role is not fully understood. This study compared two groups of patients with MDD experiencing or not BE symptoms to ascertain differences in te
Publikováno v:
International Clinical Psychopharmacology, 37, 4, pp. 166-172
International Clinical Psychopharmacology, 37, 166-172
International Clinical Psychopharmacology, 37, 166-172
Obsessive-compulsive symptoms (OCS) are often reported in patients with bipolar disorder. The aim of this study was to investigate OCS and their related clinical features in major depressive disorder (MDD). The analysis involved 482 outpatients with
Autor:
Paolo Olgiati, Alessandro Serretti
Publikováno v:
International Clinical Psychopharmacology. 37:1-8
Post-traumatic stress disorder (PTSD) and childhood maltreatment (CMT: parental neglect; emotional, physical and sexual abuse) have been linked to bipolar disorder but they are also common in major depressive disorder (MDD). Our objective was to inve
Publikováno v:
Neuropsychobiology. 80:425-436
Introduction: Irritable mood (IM) and subthreshold hypomanic symptoms are reported in half and two-fifths of major depressed subjects respectively, but their clinical and prognostic meanings remain unclear. The aim of this study was to test the clini
Autor:
Paolo Olgiati, Christoph Kraus, Joseph Zohar, Daniel Souery, Siegfried Kasper, Alessandro Serretti, Julien Mendlewicz, Stuart Montgomery
The aim of this study was to investigate attrition (dropout) during a second antidepressant trial in treatment-resistant depression. Three hundred forty-two outpatients with major depressive disorder and lack of response to a prior antidepressant wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6530a56ab4f0fd1aa0d9b87251027ab
http://hdl.handle.net/11585/713998
http://hdl.handle.net/11585/713998
Autor:
Siegfried Kasper, Stuart Montgomery, Daniel Souery, Markus Dold, Joseph Zohar, Alessandro Serretti, Julien Mendlewicz, Paolo Olgiati
Background Initial improvement in the first weeks of antidepressant (AD) treatment is a useful early predictor of complete AD response. We performed a meta-analysis of AD studies to investigate whether a partial decrease in depressive symptoms by wee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5a6210687b52d9dd0378f008547639b
http://hdl.handle.net/11585/620850
http://hdl.handle.net/11585/620850
Autor:
Alessandro Serretti, Paolo Olgiati
Publikováno v:
Human Psychopharmacology: Clinical and Experimental. 30:329-333
Objective Paroxetine titration may be difficult in older individuals as they are more sensitive to side effects. The current study extends to 6 months our previously published report in which paroxetine was started at 2.5 mg/day and slowly increased